  Chronic lymphocytic leukemia<disease> ( CLL) is the most frequent B cell malignancy in Caucasian adults. The therapeutic armamentarium against this incurable disease has recently seen a tremendous expansion with the introduction of specific pathway inhibitors and innovative immunotherapy. However , none of these approaches is curative and devoid of side effects. We have used B-cell-specific antibodies conjugated with antigens ( AgAbs) of the Epstein-Barr virus ( EBV) to efficiently expand memory CD4